How to evaluate combination therapy using interferon and nucleos(t)ide analogues

How to evaluate combination therapy using interferon and nucleos(t)ide analogues

Chronic hepatitis B is still one of the most important chronic diseases in China because of its high relevance to liver cirrhosis and hepatic cell cancer (HCC). Currently, interferon and nucleos(t)ide analogues are two main treatments for chronic hepatitis B, but they have advantages and disadvantag...

Full description

Bibliographic Details
Main Authors: CHEN Lu, XIE Qing
Format: Article
Language:zho
Published: Editorial Department of Journal of Clinical Hepatology 2016-11-01
Series:Linchuang Gandanbing Zazhi
Online Access:http://www.lcgdbzz.org/qk_content.asp?id=7798
id doaj-35362f34a36f4002ad44a3ca6b8a3c22
record_format Article
spelling doaj-35362f34a36f4002ad44a3ca6b8a3c222020-11-24T22:20:31ZzhoEditorial Department of Journal of Clinical HepatologyLinchuang Gandanbing Zazhi1001-52561001-52562016-11-0132112050205310.3969/j.issn.1001-5256.2016.11.006How to evaluate combination therapy using interferon and nucleos(t)ide analoguesCHEN Lu0XIE Qing1Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University Medical School, Shanghai 200025, ChinaDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University Medical School, Shanghai 200025, ChinaChronic hepatitis B is still one of the most important chronic diseases in China because of its high relevance to liver cirrhosis and hepatic cell cancer (HCC). Currently, interferon and nucleos(t)ide analogues are two main treatments for chronic hepatitis B, but they have advantages and disadvantages. More investigations are needed to explore better ways for treating this disease, and combination therapy might be one of the options. This article analyzes the advances in various combination therapies and points out views about the selection of combination therapies and patients.http://www.lcgdbzz.org/qk_content.asp?id=7798
collection DOAJ
language zho
format Article
sources DOAJ
author CHEN Lu
XIE Qing
spellingShingle CHEN Lu
XIE Qing
How to evaluate combination therapy using interferon and nucleos(t)ide analogues
Linchuang Gandanbing Zazhi
author_facet CHEN Lu
XIE Qing
author_sort CHEN Lu
title How to evaluate combination therapy using interferon and nucleos(t)ide analogues
title_short How to evaluate combination therapy using interferon and nucleos(t)ide analogues
title_full How to evaluate combination therapy using interferon and nucleos(t)ide analogues
title_fullStr How to evaluate combination therapy using interferon and nucleos(t)ide analogues
title_full_unstemmed How to evaluate combination therapy using interferon and nucleos(t)ide analogues
title_sort how to evaluate combination therapy using interferon and nucleos(t)ide analogues
publisher Editorial Department of Journal of Clinical Hepatology
series Linchuang Gandanbing Zazhi
issn 1001-5256
1001-5256
publishDate 2016-11-01
description Chronic hepatitis B is still one of the most important chronic diseases in China because of its high relevance to liver cirrhosis and hepatic cell cancer (HCC). Currently, interferon and nucleos(t)ide analogues are two main treatments for chronic hepatitis B, but they have advantages and disadvantages. More investigations are needed to explore better ways for treating this disease, and combination therapy might be one of the options. This article analyzes the advances in various combination therapies and points out views about the selection of combination therapies and patients.
url http://www.lcgdbzz.org/qk_content.asp?id=7798
work_keys_str_mv AT chenlu howtoevaluatecombinationtherapyusinginterferonandnucleostideanalogues
AT xieqing howtoevaluatecombinationtherapyusinginterferonandnucleostideanalogues
_version_ 1725774672878895104

Similar Items